ARPKD usually develops perinatally or in childhood, and most commonly results from missense or truncating mutations in PKHD1. The vasopressin 2 receptor antagonist tolvaptan is the only Food and Drug Administration (FDA)-approved drug for use in ADPKD, and can delay the progression of ADPKD but exhibits side effects like polyuria and liver damage (Muller et al., 2021). This evidence concerns the gene PKHD1 and autosomal dominant polycystic kidney disease.